MDP Insider Trading
Insider Ownership Percentage: 9.14%
Insider Buying (Last 12 Months): C$25,324.00
Insider Selling (Last 12 Months): C$0.00
Medexus Pharmaceuticals Insider Trading History Chart
This chart shows the insider buying and selling history at Medexus Pharmaceuticals by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Medexus Pharmaceuticals Share Price & Price History
Current Price: C$3.99
Price Change: ▼ Price Decrease of -0.3 (-6.99%)
As of 01/21/2025 05:00 PM ET
Medexus Pharmaceuticals Insider Trading History
SEC Filings (Institutional Ownership Changes) for Medexus Pharmaceuticals (TSE:MDP)
8.32% of Medexus Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Treosulfan, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; Tricovel tablets with Biogenina to reduce hair shedding due to Telogen Eflluvium; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.
Read More on Medexus Pharmaceuticals
Today's Range
Now: C$3.99
52 Week Range
Now: C$3.99
Volume
98,130 shs
Average Volume
91,003 shs
Market Capitalization
C$97.87 million
P/E Ratio
79.80
Dividend Yield
N/A
Beta
1.96
Who are the company insiders with the largest holdings of Medexus Pharmaceuticals?